Freeline Reports October 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Plugin JSON Content Importer Pro not running: Check Licence! Check that a Licence is active for https://freeline.life
You might also like
Freeline Initiates Dosing of Second Cohort in B-LIEVE Dose Confirmation Trial of FLT180a in Hemophilia B
Freeline Granted ILAP Designation in United Kingdom by MHRA for FLT201, an Investigational Gene Therapy for the Treatment of Gaucher Disease
Freeline Announces First Patient Dosed in the Phase 1/2 B-LIEVE Dose-Confirmation Trial in Hemophilia B
New England Journal of Medicine Publishes Positive Long-Term Data on Freeline’s Gene Therapy Candidate FLT180a for People with Hemophilia B
Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Freeline Reports Second Quarter 2023 Financial Results and Business Highlights
Get in touch

+44 (0)1438 906870
contact@freeline.life

Follow us on our social channels